Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating a single clinical milestone inside Protara Therapeutics’ dense SEC disclosures can feel like hunting for a nucleotide in a genome. R&D expense tables, cash-runway projections, and FDA feedback notes are scattered across hundreds of pages—yet every line matters when a biotech’s value hinges on TARA-002 trial data or IV Choline Chloride approvals.
Stock Titan solves this problem in minutes. Our AI reads each new 10-K annual report and 10-Q quarterly earnings report, then explains how updated trial enrollment, orphan-drug incentives, and liquidity ratios affect valuation. Need the latest Protara Therapeutics insider trading Form 4 transactions? Real-time alerts flag executive stock moves as soon as EDGAR posts them, giving you instant visibility into management’s conviction.
Investors often ask, “Where can I find Protara Therapeutics’ Form 4 insider transactions in real time?” or “How do I interpret the company’s 8-K material events explained?”—you’ll find both here, distilled into plain language. Our coverage includes:
- 8-K events that summarize clinical hold notices or trial achievements
- Proxy statement executive compensation details tied to milestone bonuses
- Side-by-side views of cash burn trends across filings
- Protara Therapeutics earnings report filing analysis with quarter-over-quarter R&D variance
Every document—whether it’s a Protara Therapeutics annual report 10-K simplified or a sudden capital raise disclosed in an 8-K—streams to your dashboard the moment it hits EDGAR. Our AI-powered summaries transform complex biotech jargon into clear takeaways so you can focus on decisions, not page counts. Understanding Protara Therapeutics SEC documents with AI has never been easier.
Protara Therapeutics filed its quarterly report, showing a net loss of
Liquidity remained solid with unrestricted cash, cash equivalents and marketable debt securities of
Program updates: In NMIBC, interim ADVANCED-2 data (April 2025 cutoff) showed complete response rates in BCG‑Unresponsive patients of
Protara Therapeutics, Inc. furnished its financial results for the quarter ended September 30, 2025 via a press release attached as Exhibit 99.1.
The disclosure was provided under Item 2.02 and is designated as furnished, not filed, under the Exchange Act. The company’s common stock trades on The Nasdaq Global Market under the symbol TARA.
RA Capital and affiliated individuals report shared beneficial ownership of 1,971,765 shares of Protara Therapeutics common stock, representing a 4.99% stake. The position reflects 1,039,295 directly held shares plus pre-funded warrants exercisable for up to 1,400,144 additional shares, but exercise is restricted by 9.99% and 4.99% beneficial ownership blockers. The 4.99% blocker currently limits exercise so reported beneficial ownership is capped at 1,971,765 shares. RA Capital serves as investment adviser and holds sole voting and dispositive power over the Fund's holdings; the filers disclaim group status and broader beneficial ownership except as required by Section 13(d).
Protara Therapeutics, Inc. is the subject of a Schedule 13G/A disclosing institutional holdings in its common stock. Janus Henderson Group plc reports beneficial ownership of 4,102,620 shares, representing 10.6% of the class, with shared voting and dispositive power over those shares. A related vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports beneficial ownership of 3,512,932 shares, or 9.1%. The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The disclosure includes a power of attorney authorizing certain compliance officers to file required reports.
Protara Therapeutics, Inc. filed a Form S-8 to register an additional 2,800,000 shares of common stock for issuance under its 2024 Equity Incentive Plan, following a board amendment adopted on April 17, 2025 and stockholder approval at the annual meeting on June 11, 2025. The filing incorporates by reference the company’s prior Form S-8 (filed August 6, 2024) and specified SEC reports, including the Annual Report filed March 5, 2025 and Quarterly Reports filed May 8, 2025 and August 11, 2025.
The registration statement discloses corporate governance items such as indemnification provisions and the inclusion of a DGCL 102(b)(7) limitation on director liability in the certificate of incorporation, and indicates the company is a non-accelerated filer and a smaller reporting company.
Protara Therapeutics is a clinical-stage biopharmaceutical company advancing TARA-002 (cell therapy) and IV Choline Chloride (intravenous choline) and has no product revenues. For the six months ended June 30, 2025 the company reported a net loss of $26.9 million versus $20.6 million in the prior year period, driven by higher research and development and general and administrative expenses. Cash and cash equivalents declined to $31.5 million while marketable debt securities increased after purchases, leaving $145.6 million in unrestricted cash and marketable securities and $115.3 million in working capital, which management states is sufficient for at least twelve months.
The company highlighted clinical progress: interim ADVANCED-2 data showed high complete response rates in small cohorts (BCG-Unresponsive 100% any-time CR 5/5; BCG-Naive 76% any-time CR 16/21) with mostly Grade 1 adverse events and no Grade 3+ treatment-related events. IV Choline Chloride received FDA Fast Track and orphan considerations and patents through 2041; Protara plans to initiate the THRIVE-3 registrational trial in Q3 2025 and obtained EU-CTR approval in July 2025. Recent financings include a December 2024 public offering (gross ~$100.1M, net ~$93.4M) and an April 2024 private placement (net ~$41.96M). The company notes it will need additional capital to fully execute its clinical plans.
On August 11, 2025, Protara Therapeutics, Inc. announced that it released its financial results for the quarter ended June 30, 2025 via a press release attached as Exhibit 99.1 to this Form 8-K. The filing explicitly states the press release and related information are being furnished and shall not be deemed filed under the Exchange Act or incorporated by reference into other filings unless expressly stated. The 8-K lists Exhibits 99.1 and 104 and is signed by Chief Financial Officer Patrick Fabbio. No financial figures or operating metrics appear in the 8-K text; readers must consult Exhibit 99.1 for the detailed results.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
